Sector News

Pfizer links with SidekickHealth for digital health solution

June 30, 2020
Life sciences

Pfizer has linked with Nordic group SidekickHealth to launch a digital therapeutics platform designed to empower patients to take more control of their own health and boost wellbeing across Europe.

According to the groups, scientific expertise and digital technologies have been combined to give patients a new tool to help them maintain healthy lifestyles and improve disease management and quality of life, while providing guidance and resources to facilitate communication with healthcare professionals.

The platform focuses on a number of therapeutic areas. First, for patients in Finland suffering from ulcerative colitis and Crohn’s disease, and then for patients with rheumatoid arthritis, atopic dermatitis and psoriatic arthritis, with plans to expand to other European countries this year and beyond.

The platform is designed to motivate patients to manage their nutrition, exercise, sleep, stress and medication adherence, as well as provide educational information and links to healthcare professionals and other patients.

“At Pfizer we are committed to enabling healthy living, and as part of this we are constantly looking for new partners and digital solutions that can significantly improve the lives of patients,” said Rob Day, Western Europe Cluster Lead, Inflammation and Immunology Group at Pfizer. “Partnering with digital experts such as Sidekick will further support Pfizer’s breakthrough therapies in an area where the burden of disease among patients is significant.”

By: Selina McKee

Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.